MX2018003320A - Cristal novedoso de compuesto piperazina. - Google Patents

Cristal novedoso de compuesto piperazina.

Info

Publication number
MX2018003320A
MX2018003320A MX2018003320A MX2018003320A MX2018003320A MX 2018003320 A MX2018003320 A MX 2018003320A MX 2018003320 A MX2018003320 A MX 2018003320A MX 2018003320 A MX2018003320 A MX 2018003320A MX 2018003320 A MX2018003320 A MX 2018003320A
Authority
MX
Mexico
Prior art keywords
new crystal
piperazine compound
crystal
present
piperazine
Prior art date
Application number
MX2018003320A
Other languages
English (en)
Inventor
Shinichi Aoki
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2018003320A publication Critical patent/MX2018003320A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objeto a ser resuelto por la presente invención es proveer un cristal superior en estabilidad de almacenamiento y en higroscopía, en particular, mientras asegura suficiente capacidad de reproducción; la presente invención provee cristales de un monohidrato de 4-((1-metilpirrol-2-il)-carbonil)-N-(4-(4-morfolin- 1-il-carbonilpiperidin-1-il)-fenil)-1-piperazinacarboxamida.
MX2018003320A 2015-09-17 2016-09-16 Cristal novedoso de compuesto piperazina. MX2018003320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015184022 2015-09-17
PCT/JP2016/077547 WO2017047791A1 (ja) 2015-09-17 2016-09-16 ピペラジン化合物の新規結晶

Publications (1)

Publication Number Publication Date
MX2018003320A true MX2018003320A (es) 2018-05-30

Family

ID=58289428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003320A MX2018003320A (es) 2015-09-17 2016-09-16 Cristal novedoso de compuesto piperazina.

Country Status (22)

Country Link
US (1) US20180258069A1 (es)
EP (1) EP3351542B1 (es)
JP (1) JP6944372B2 (es)
KR (1) KR102587705B1 (es)
CN (1) CN108026068A (es)
AU (1) AU2016324121B2 (es)
BR (1) BR112018003448A2 (es)
CA (1) CA2999009C (es)
DK (1) DK3351542T3 (es)
ES (1) ES2901157T3 (es)
HK (1) HK1247921A1 (es)
HU (1) HUE057813T2 (es)
MA (1) MA42839A (es)
MX (1) MX2018003320A (es)
MY (1) MY193595A (es)
PH (1) PH12018500399A1 (es)
PL (1) PL3351542T3 (es)
PT (1) PT3351542T (es)
RU (1) RU2018113722A (es)
SG (2) SG11201801295WA (es)
TW (1) TWI707851B (es)
WO (1) WO2017047791A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
SG173865A1 (en) * 2009-03-09 2011-09-29 Taiho Pharmaceutical Co Ltd Piperazine compound capable of inhibiting prostaglandin d synthase
MY161134A (en) * 2010-01-22 2017-04-14 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
JP6130701B2 (ja) * 2012-04-01 2017-05-17 エシャシ ファーマ リミテッドEshyasi Pharma Limited (2rs)−1−ジメチルアミノ−3−{2−[2−(3−メトキシフェニル)エチル]フェノキシ}プロパン−2−イルコハク酸水素塩酸塩の工業的製造方法
JP5999686B2 (ja) * 2012-04-05 2016-09-28 ロンシール工業株式会社 耐熱性ポリ乳酸系成形体、およびその製造方法
SG11201501043TA (en) * 2012-09-19 2015-04-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition for oral administration with improved dissolution and/or absorption

Also Published As

Publication number Publication date
KR102587705B1 (ko) 2023-10-12
TW201720818A (zh) 2017-06-16
SG11201801295WA (en) 2018-03-28
EP3351542A1 (en) 2018-07-25
US20180258069A1 (en) 2018-09-13
WO2017047791A1 (ja) 2017-03-23
CA2999009C (en) 2023-05-23
RU2018113722A (ru) 2019-10-18
HK1247921A1 (zh) 2018-10-05
MY193595A (en) 2022-10-19
TWI707851B (zh) 2020-10-21
EP3351542B1 (en) 2021-11-17
ES2901157T3 (es) 2022-03-21
SG10201912021VA (en) 2020-02-27
JP6944372B2 (ja) 2021-10-06
AU2016324121A1 (en) 2018-04-26
CN108026068A (zh) 2018-05-11
MA42839A (fr) 2018-07-25
BR112018003448A2 (pt) 2018-09-25
JPWO2017047791A1 (ja) 2018-07-05
PH12018500399A1 (en) 2018-08-29
WO2017047791A9 (ja) 2017-05-18
PL3351542T3 (pl) 2022-02-14
AU2016324121B2 (en) 2020-08-20
PT3351542T (pt) 2021-12-21
KR20180051628A (ko) 2018-05-16
HUE057813T2 (hu) 2022-06-28
EP3351542A4 (en) 2019-04-24
DK3351542T3 (da) 2022-01-03
RU2018113722A3 (es) 2019-12-23
CA2999009A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
IL257390B (en) Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
CL2017001617A1 (es) Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
AU2014267235A8 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
TWD175732S (zh) 錶盤
SG11201506093SA (en) N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
EA201691244A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
PH12017500530A1 (en) Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
MX2018005803A (es) Forma novedosa de espirodiclofeno, procedimiento de preparacion y uso de la misma.
AR098592A1 (es) Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos
MX366651B (es) Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma.
PH12018500399A1 (en) New crystal of piperazine compound
TW201611832A (en) Icaritin compound and application thereof
PL3607018T3 (pl) Wodne dyspersje o wysokiej stabilności do klejów i szczeliw
TH1801001560A (th) ผลึกใหม่ของสารประกอบไพเพอราซีน
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.
GB2561750A (en) Novel crystalline form of thifensulfuron-methyl, process for preparation and use thereof
BR112017018248A2 (pt) composto metalorgânico
UA90397U (uk) Валок валкової дробарки